Trial Profile
AMPOWER A Single-arm, Phase III, Open Label, Multi-center, Study in Women Aged 18-35 Years of the Contraceptive Efficacy and Safety of Phexxi (Previously Referred to as AMPHORA) Contraceptive Vaginal Gel
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jul 2022
Price :
$35
*
At a glance
- Drugs Citric acid/lactic acid/potassium bitartrate (Primary)
- Indications Pregnancy
- Focus Registrational; Therapeutic Use
- Acronyms AMPOWER
- Sponsors Evofem Biosciences
- 12 Jul 2022 According to an Evofem media release, results from this study will be presented at the upcoming American Society for Reproductive Medicine (ASRM) 2022 Scientific Congress & Expo.
- 16 Jun 2022 Post-hoc results presented in an Evofem Biosciences media release.
- 08 May 2022 Results (n=1339) of a post-hoc analysis determining women who experienced urinary tract infections while receiving Vaginal pH modulator presented at the 71st Annual Clinical Meeting of the American College of Obstetricians and Gynecologists